secwatch.observer — SEC 8-K summary
======================================

Issuer:     Autolus Therapeutics plc (AUTL)
CIK:        0001730463
Form:       8-K
Filed at:   2024-09-19T23:59:59+00:00
Accession:  0001730463-24-000104
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Autolus Therapeutics appoints Matthias Will, M.D. as Chief Development Officer
------------------------------------------------------------------------------

- Dr. Will joins as CDO effective September 30, 2024.
- Previously CMO at Dren Bio and VP Clinical Development at CRISPR Therapeutics.
- Will lead development organization, including obe-cel for relapsed/refractory adult B-ALL.
- Appointment comes as Autolus prepares to commercialize first product obe-cel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730463/000173046324000104/0001730463-24-000104-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730463/000173046324000104/autl-20240913.htm
  HTML page:      https://secwatch.observer/filing/0001730463-24-000104

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer